Dr. Reddy's Laboratories Limited (DRREDDY) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Total Assets Chart for Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (DRREDDY) total assets for FY2026 were INR 579.3B, a 17.5% change from FY2025. Dr. Reddy's Laboratories Limited's total assets grew from INR 11.8B in 2001 to INR 579.3B in 2026 (4793.2% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 16.9%, 10-year CAGR of 10.8%, 20-year CAGR of 11.2%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (Indian Rupees)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
₹1.02T
Implied Share Price
₹1229.50
Enterprise Value
₹944.51B
Revenue (TTM)
₹329.84B
EBITDA
₹49.93B
Profit Margin
8.49%
Trailing P/E
36.60
Forward P/E
25.97
Price/Book (MRQ)
2.48
Price/Sales (TTM)
3.11
EV/EBITDA
14.17
EV/Revenue
2.85
Dividend Yield
0.65%
Book Value
₹463.83
Free Cash Flow (FY2026)
₹30.51B
Free Cash Flow Yield
2.98%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.